PPARγ agonists have been shown to inhibit the development of colon cancer, highlighting the receptor’s potential as a target for therapeutic intervention in the treatment of colorectal cancer (CRC) [30, 31]. This evidence concerns the gene PPARG and colonic neoplasm.